Dark Classics in Chemical Neuroscience: Δ9-Tetrahydrocannabinol
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Cannabis ( Cannabis sativa ) is the most widely used illicit drug in the world, with an estimated 192 million users globally. The main psychoactive component of cannabis is (−)- trans -Δ 9 -tetrahydrocannabinol (Δ 9 -THC), a compound with a diverse range of pharmacological actions. The unique and distinctive intoxication caused by Δ 9 -THC primarily reflects partial agonist action at central cannabinoid type 1 (CB 1 ) receptors. Δ 9 -THC is an approved therapeutic treatment for a range of conditions, including chronic pain, chemotherapy-induced nausea and vomiting, and multiple sclerosis, and is being investigated in indications such as anorexia nervosa, agitation in dementia, and Tourette’s syndrome. It is available as a regulated pharmaceutical in products such as Marinol, Sativex, and Namisol as well as in an ever-increasing range of unregistered medicinal and recreational cannabis products. While cannabis is an ancient medicament, contemporary use is embroiled in legal, scientific, and social controversy, much of which relates to the potential hazards and benefits of Δ 9 -THC itself. Robust contemporary debate surrounds the therapeutic value of Δ 9 -THC in different diseases, its capacity to produce psychosis and cognitive impairment, and the addictive and “gateway” potential of the drug. This review will provide a profile of the chemistry, pharmacology, and therapeutic uses of Δ 9 -THC as well as the historical and societal import of this unique, distinctive, and ubiquitous psychoactive substance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159
The orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568
Human Cannabinoid Pharmacokinetics
Huestis, M. A. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790152 · Cited by 1,102
Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan‐Wright, E. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13250 · Cited by 1,039
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01166.x · Cited by 946
Phytocannabinoids: a unified critical inventory
Hanuš, L. O., Meyer, S. M., Muñoz, E., Taglialatela-Scafati, O., & Appendino, G. (2016) · Natural Product Reports · doi:10.1039/c6np00074f · Cited by 844
Adverse effects of medical cannabinoids: a systematic review
Wang, T., Collet, J.-P., Shapiro, S., & Ware, M. A. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.071178 · Cited by 357
Cited by
Santiago, M., Sachdev, S., Arnold, J. C., McGregor, I. S., & Connor, M. (2019) · Cannabis & Cannabinoid Research · doi:10.1089/can.2019.0016 · Cited by 112
Self-citationThe association of cannabis use and cardiac dysrhythmias: a systematic review
Richards, J. R., Blohm, E., Toles, K. A., Jarman, A. F., Ely, D. F., & Elder, J. W. (2020) · Clinical Toxicology · doi:10.1080/15563650.2020.1743847 · Cited by 82
“Both CB receptor subtypes are also located in the myocardium and vascular endothelium [71,72].”
BackgroundCannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis
Filippini, G., Minozzi, S., Borrelli, F., Cinquini, M., & Dwan, K. (2022) · Cochrane Database Systematic Reviews · doi:10.1002/14651858.cd013444.pub2 · Cited by 75
Metadata
- Authors
- Banister, S. D., Arnold, J. C., Connor, M., Glass, M., & McGregor, I. S.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-01-28
- Volume
- 10
- Issue
- 5
- Pages
- 2160-2175
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2913034299
- Cited by
- 86
- References
- 19
- FWCI
- 5.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dark Classics in Chemical Neuroscience: Δ9-Tetrahydrocannabinol. https://app.cochat.ai/papers/10.1021/acschemneuro.8b00651
- The paper
- Banister, S. D., Arnold, J. C., Connor, M., Glass, M., & McGregor, I. S. (2019). Dark Classics in Chemical Neuroscience: Δ9-Tetrahydrocannabinol. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.8b00651
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.